TEST:

GeneseeqPrime™

"Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval. These approvals signify that GeneseeqPrime™ and GeneseeqPrime™ HRD are suitable for solid tumor genomic profiling, while Hemasalus™ DNA/Hemarna™ RNA is cleared for hematological cancer genomic profiling."

"Geneseeq co-published a study with Princess Margaret Cancer Centre in the JCO Precision Oncology journal, investigating the use of ctDNA as a prognostic biomarker for immunotherapy in early-phase clinical trials...Using the GeneseeqPrime™ panel, the researchers evaluated the variant allele fraction (VAF) of mutations in ctDNAs at baseline and before the second cycle of treatment (3-4 weeks) with a sequencing depth of around 5000X."

"A recent prospective study published in the Drug Resistance Updates, led by Sun Yat-sen University Cancer Center and Geneseeq Technology Inc. demonstrated that the analysis of ctDNA points to drug resistance mechanisms to the combination of vemurafenib, irinotecan, and cetuximab (VIC) in BRAFV600E mCRC patients, allowing accurate guidance for clinicians in personalized treatment strategies...Tissue and plasma samples were profiled using whole-exome sequencing and the 425-gene Geneseeqprime panel sequencing, respectively."

"A recent prospective study published in the Journal of Hematology & Oncology, led by Jiangsu Oncology Hospital and Geneseeq demonstrated the clinical utility of longitudinal ctDNA monitoring in MRD detection and prognosis prediction in patients with resectable NSCLC...Both tissue and plasma samples were sequenced using the 425-gene Geneseeqprime panel."

"Geneseeq is teaming up with Hospital de Base in Sao José do Rio Preto, Brazil to build an NGS-based precision oncology diagnostic lab in-house to advance clinical research and offer comprehensive genetic testing to cancer patients in Brazil. Under the terms of the agreement, Geneseeq and Hospital de Base will co-build the NGS lab and establish a variety of Geneseeq’s NGS-based genomic profiling tests, consisting of comprehensive pan-cancer gene panels and cancer type-specific gene panels...The comprehensive panel GeneseeqPrime analyzes 437 cancer-related genes across all solid tumors while reporting microsatellite instability (MSI) and tumor mutation burden (TMB). GeneseeqPrime HRD, a test that integrates GeneseeqPrime with homologous recombination deficiency (HRD) score evaluation to inform the treatment selection of PARP inhibitors will also be available."

"Geneseeq will participate in the ASCO with eight interesting topics spanning novel biomarkers for immunotherapy, early detection, minimal residue disease as well as the impact of psychological distress on the disease outcome of the patients."